These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 25178561)

  • 1. Clinical behavior of chromophobe renal cell carcinoma is less aggressive than that of clear cell renal cell carcinoma, independent of Fuhrman grade or tumor size.
    Steffens S; Roos FC; Janssen M; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Junker K; Kuczyk MA; Schrader AJ;
    Virchows Arch; 2014 Oct; 465(4):439-44. PubMed ID: 25178561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Does chromophobe renal cell carcinoma have better survival than clear cell renal cell carcinoma? A clinical-based cohort study and meta-analysis.
    Jiang HM; Wei JH; Zhang ZL; Fang Y; Zhou BF; Chen ZH; Lu J; Liao B; Zhou FJ; Luo JH; Chen W
    Int Urol Nephrol; 2016 Feb; 48(2):191-9. PubMed ID: 26589610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinicopathological and survival analysis of clinically advanced papillary and chromophobe renal cell carcinoma.
    Kaldany A; Paulucci DJ; Kannappan M; Beksac AT; Anastos H; Okhawere K; Sfakianos JP; Badani KK
    Urol Oncol; 2019 Oct; 37(10):727-734. PubMed ID: 31174958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chromophobe Renal Cell Carcinoma: Results From a Large Single-Institution Series.
    Casuscelli J; Becerra MF; Seier K; Manley BJ; Benfante N; Redzematovic A; Stief CG; Hsieh JJ; Tickoo SK; Reuter VE; Coleman JA; Russo P; Ostrovnaya I; Hakimi AA
    Clin Genitourin Cancer; 2019 Oct; 17(5):373-379.e4. PubMed ID: 31326335
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Fuhrman grading system has no prognostic value in patients with nonsarcomatoid chromophobe renal cell carcinoma.
    Steffens S; Janssen M; Roos FC; Becker F; Steinestel J; Abbas M; Steinestel K; Wegener G; Siemer S; Thüroff JW; Hofmann R; Stöckle M; Schrader M; Hartmann A; Hasenfus A; Kuczyk MA; Junker K; Schrader AJ;
    Hum Pathol; 2014 Dec; 45(12):2411-6. PubMed ID: 25305793
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grading Chromophobe Renal Cell Carcinoma: Evidence for a Four-tiered Classification Incorporating Coagulative Tumor Necrosis.
    Avulova S; Cheville JC; Lohse CM; Gupta S; Potretzke TA; Tsivian M; Thompson RH; Boorjian SA; Leibovich BC; Potretzke AM
    Eur Urol; 2021 Feb; 79(2):225-231. PubMed ID: 33172723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of clinicopathological features and prognosis in 68 patients with chromophobe renal cell carcinoma].
    Huang JW; Zhang J; Dong BJ; Kong W; Niu SX; Chen YH; Xue W; Liu DM; Huang YR
    Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):510-3. PubMed ID: 22967469
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An epidemiological and clinicopathological study of type 1 vs. type 2 morphological subtypes of papillary renal cell carcinoma- results from a nation-wide study covering 50 years in Iceland.
    Runarsson TG; Bergmann A; Erlingsdottir G; Petursdottir V; Heitmann LA; Johannesson A; Asbjornsson V; Axelsson T; Hilmarsson R; Gudbjartsson T
    BMC Urol; 2024 May; 24(1):105. PubMed ID: 38741053
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic and Lipidomic Reprogramming in Renal Cell Carcinoma Subtypes Reflects Regions of Tumor Origin.
    Schaeffeler E; Büttner F; Reustle A; Klumpp V; Winter S; Rausch S; Fisel P; Hennenlotter J; Kruck S; Stenzl A; Wahrheit J; Sonntag D; Scharpf M; Fend F; Agaimy A; Hartmann A; Bedke J; Schwab M
    Eur Urol Focus; 2019 Jul; 5(4):608-618. PubMed ID: 29452772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of renal cell carcinoma histological subtype and fuhrman grade using
    Nakajima R; Nozaki S; Kondo T; Nagashima Y; Abe K; Sakai S
    Eur Radiol; 2017 Nov; 27(11):4866-4873. PubMed ID: 28523353
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel tumor grading scheme for chromophobe renal cell carcinoma: prognostic utility and comparison with Fuhrman nuclear grade.
    Paner GP; Amin MB; Alvarado-Cabrero I; Young AN; Stricker HJ; Moch H; Lyles RH
    Am J Surg Pathol; 2010 Sep; 34(9):1233-40. PubMed ID: 20679882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor volume: a new prognostic factor of oncological outcome of localized clear cell renal cell carcinoma.
    Chen SH; Xu LY; Wu YP; Ke ZB; Huang P; Lin F; Li XD; Xue XY; Wei Y; Zheng QS; Xu N
    BMC Cancer; 2021 Jan; 21(1):79. PubMed ID: 33468079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differences in Overall and Cancer-specific Survival of Patients Presenting With Chromophobe Versus Clear Cell Renal Cell Carcinoma: A Propensity Score Matched Analysis.
    Frees S; Kamal MM; Knoechlein L; Bell R; Ziesel C; Neisius A; Thomas C; Brenner W; Jäger W; Thüroff JW; Roos FC
    Urology; 2016 Dec; 98():81-87. PubMed ID: 27262395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Histologic subtype needs to be considered after partial nephrectomy in patients with pathologic T1a renal cell carcinoma: papillary vs. clear cell renal cell carcinoma.
    Yoo S; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Kim CS
    J Cancer Res Clin Oncol; 2017 Sep; 143(9):1845-1851. PubMed ID: 28451753
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PRMT1 expression in renal cell tumors- application in differential diagnosis and prognostic relevance.
    Filipović J; Bosić M; Ćirović S; Životić M; Dunđerović D; Đorđević D; Živković-Perišić S; Lipkovski A; Marković-Lipkovski J
    Diagn Pathol; 2019 Oct; 14(1):120. PubMed ID: 31655611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clear cell and non-clear cell renal cell carcinoma in young adults: clinicopathological features, survival outcomes and prognostic factors.
    Xue Z; Tang S; Ou J; Fang Y; Qiu M; Hong K; Tian X; Zhang H; Liu C; Ma L; Zhang S
    World J Urol; 2024 May; 42(1):364. PubMed ID: 38819448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Grading Challenges and Prognostic Insights in Chromophobe Renal Cell Carcinoma: A Retrospective Study of 72 Patients.
    Papanikolaou D; Sokolakis I; Moysidis K; Pyrgidis N; Bobos M; Meditskou S; Hatzimouratidis K
    Medicina (Kaunas); 2024 Jun; 60(6):. PubMed ID: 38929613
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Postoperative prognosis of chromophobic renal cell carcinoma: comparative analysis of the multinational CORONA database].
    May M; Zigeuner R; Aziz A; Cindolo L; Gilfrich C; Schips L; De Cobelli O; Rocco B; De Nunzio C; Tubaro A; Coman I; Feciche B; Truss M; Hoschke B; Dalpiaz O; Stoltze A; Fenske F; Fritsche HM; Chromecki T; Lebentrau S; Figenshau RS; Madison K; Sánchez-Chapado M; Del Carmen Santiago Martin M; Salzano L; Lotrecchiano G; Joniau S; Waidelich R; Stief CG; Brookman-May S; ;
    Urologe A; 2014 Feb; 53(2):228-35. PubMed ID: 23836364
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis.
    Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Mistretta FA; Tian Z; Musi G; Montanari E; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
    Urol Oncol; 2020 May; 38(5):506-514. PubMed ID: 32139292
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.